The structure of the NPC1L1 N-terminal domain in a closed conformation

Hyock Joo Kwon, Maya Palnitkar, Johann Deisenhofer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: NPC1L1 is the molecular target of the cholesterol lowering drug Ezetimibe and mediates the intestinal absorption of cholesterol. Inhibition or deletion of NPC1L1 reduces intestinal cholesterol absorption, resulting in reduction of plasma cholesterol levels. Principal Findings: Here we present the 2.8 Å crystal structure of the N-terminal domain (NTD) of NPC1L1 in the absence of cholesterol. The structure, combined with biochemical data, reveals the mechanism of cholesterol selectivity of NPC1L1. Comparison to the cholesterol free and bound structures of NPC1(NTD) reveals that NPC1L1(NTD) is in a closed conformation and the sterol binding pocket is occluded from solvent. Conclusion: The structure of NPC1L1(NTD) reveals a degree of flexibility surrounding the entrance to the sterol binding pocket, suggesting a gating mechanism that relies on multiple movements around the entrance to the sterol binding pocket.

Original languageEnglish (US)
Article numbere18722
JournalPLoS One
Volume6
Issue number4
DOIs
StatePublished - 2011

Fingerprint

Conformations
Cholesterol
cholesterol
Sterols
sterols
Intestinal Absorption
intestinal absorption
crystal structure
Crystal structure
Plasmas
drugs
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The structure of the NPC1L1 N-terminal domain in a closed conformation. / Kwon, Hyock Joo; Palnitkar, Maya; Deisenhofer, Johann.

In: PLoS One, Vol. 6, No. 4, e18722, 2011.

Research output: Contribution to journalArticle

@article{6e1c18377d13429fa5af243830cf28b8,
title = "The structure of the NPC1L1 N-terminal domain in a closed conformation",
abstract = "Background: NPC1L1 is the molecular target of the cholesterol lowering drug Ezetimibe and mediates the intestinal absorption of cholesterol. Inhibition or deletion of NPC1L1 reduces intestinal cholesterol absorption, resulting in reduction of plasma cholesterol levels. Principal Findings: Here we present the 2.8 {\AA} crystal structure of the N-terminal domain (NTD) of NPC1L1 in the absence of cholesterol. The structure, combined with biochemical data, reveals the mechanism of cholesterol selectivity of NPC1L1. Comparison to the cholesterol free and bound structures of NPC1(NTD) reveals that NPC1L1(NTD) is in a closed conformation and the sterol binding pocket is occluded from solvent. Conclusion: The structure of NPC1L1(NTD) reveals a degree of flexibility surrounding the entrance to the sterol binding pocket, suggesting a gating mechanism that relies on multiple movements around the entrance to the sterol binding pocket.",
author = "Kwon, {Hyock Joo} and Maya Palnitkar and Johann Deisenhofer",
year = "2011",
doi = "10.1371/journal.pone.0018722",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - The structure of the NPC1L1 N-terminal domain in a closed conformation

AU - Kwon, Hyock Joo

AU - Palnitkar, Maya

AU - Deisenhofer, Johann

PY - 2011

Y1 - 2011

N2 - Background: NPC1L1 is the molecular target of the cholesterol lowering drug Ezetimibe and mediates the intestinal absorption of cholesterol. Inhibition or deletion of NPC1L1 reduces intestinal cholesterol absorption, resulting in reduction of plasma cholesterol levels. Principal Findings: Here we present the 2.8 Å crystal structure of the N-terminal domain (NTD) of NPC1L1 in the absence of cholesterol. The structure, combined with biochemical data, reveals the mechanism of cholesterol selectivity of NPC1L1. Comparison to the cholesterol free and bound structures of NPC1(NTD) reveals that NPC1L1(NTD) is in a closed conformation and the sterol binding pocket is occluded from solvent. Conclusion: The structure of NPC1L1(NTD) reveals a degree of flexibility surrounding the entrance to the sterol binding pocket, suggesting a gating mechanism that relies on multiple movements around the entrance to the sterol binding pocket.

AB - Background: NPC1L1 is the molecular target of the cholesterol lowering drug Ezetimibe and mediates the intestinal absorption of cholesterol. Inhibition or deletion of NPC1L1 reduces intestinal cholesterol absorption, resulting in reduction of plasma cholesterol levels. Principal Findings: Here we present the 2.8 Å crystal structure of the N-terminal domain (NTD) of NPC1L1 in the absence of cholesterol. The structure, combined with biochemical data, reveals the mechanism of cholesterol selectivity of NPC1L1. Comparison to the cholesterol free and bound structures of NPC1(NTD) reveals that NPC1L1(NTD) is in a closed conformation and the sterol binding pocket is occluded from solvent. Conclusion: The structure of NPC1L1(NTD) reveals a degree of flexibility surrounding the entrance to the sterol binding pocket, suggesting a gating mechanism that relies on multiple movements around the entrance to the sterol binding pocket.

UR - http://www.scopus.com/inward/record.url?scp=79954566374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954566374&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0018722

DO - 10.1371/journal.pone.0018722

M3 - Article

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e18722

ER -